BrainQuant SA Revolutionizes Neurodegenerative Diseases Detection

BrainQuant SA is a Wyss Center Geneva spin-off co-founded in partnership with EPFL, University of Geneva (UNIGE), and HCK Healthcare Konnect. The new company, led by internationally recognized experts in neuroradiology, bioengineering, and digital health, is poised to transform how neurodegenerative diseases are detected.

BrainQuant harnesses the power of artificial intelligence to analyze Arterial Spin Labeling (ASL) MRI sequences. This advanced imaging technique reveals subtle changes in cerebral blood flow—often before structural damage becomes visible—allowing for earlier detection of cognitive decline, including conditions such as Alzheimer’s disease.

“Brain MRI is standard of care for most patients with suspected neurodegenerative disease. A significant advantage of ASL sequences in MRI is that it can be simply added to standard MRI protocol as a one-shot imaging assessment of brain structure and brain function. The performance of ASL is nearly equivalent to FDG PET scans while offering a non-invasive alternative, eliminating the need for another expensive PET imaging appointment and radioactive tracer injection. This efficiency supports its widespread adoption in routine clinical practice”,  said Prof. Sven Haller, Chief Medical Officer and co-founder of BrainQuant.

“Our collaboration with EPFL, Université de Genève, and BrainQuant represents a significant advancement in non-invasive and accessible diagnostic alternatives. By integrating these innovations into routine clinical practices, we can enhance early detection and treatment of neurodegenerative diseases”, said Erwin Böttinger, CEO of the Wyss Center in Geneva.

➡️ Source: Wyss Center
📸 L to R: Craig Cook, Alessandro Volz, Marwan Senhaji, Sven Haller, Dmitri Van de Ville, Jon Mark Walls. © Wyss Center